CryoPort (NASDAQ:CYRX) Sets New 12-Month High After Analyst Upgrade

by · The Markets Daily

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report)’s share price reached a new 52-week high on Friday after KeyCorp raised their price target on the stock from $17.00 to $20.00. KeyCorp currently has an overweight rating on the stock. CryoPort traded as high as $19.29 and last traded at $18.7240, with a volume of 200,535 shares changing hands. The stock had previously closed at $16.05.

A number of other equities research analysts have also recently issued reports on the stock. Needham & Company LLC upped their price objective on shares of CryoPort from $19.00 to $28.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Roth Capital restated a “buy” rating and set a $21.00 target price on shares of CryoPort in a report on Friday, August 7th. Piper Sandler raised CryoPort to a “buy” rating in a research report on Tuesday, October 13th. Finally, Guggenheim upped their price target on CryoPort from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.69.

Check Out Our Latest Stock Report on CYRX

Insider Activity at CryoPort

In related news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the transaction, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Trending Headlines about CryoPort

Here are the key news stories impacting CryoPort this week:

  • Positive Sentiment: KeyCorp raised its price target to $20 from $17 and maintained an Overweight rating. Needham lifted its target to $28 from $19 and kept its Buy rating. Read More. Read More.
  • Positive Sentiment: Third-quarter revenue grew 14% year over year to $50.2 million, topping analysts’ expectations of $48.66 million. Commercial cell and gene therapy revenue increased 20%. CryoPort also raised its 2026 revenue outlook to $197 million–$199 million and reported supporting a record 788 clinical trials and 23 commercially approved therapies. Read More.
  • Negative Sentiment: The company reported a Q3 loss of $0.25 per share, missing consensus estimates of a loss of $0.18–$0.19 and worsening from a loss of $0.18 a year earlier. Read More.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue acquired a new position in shares of CryoPort during the third quarter worth approximately $40,000. State of Wyoming boosted its position in shares of CryoPort by 9.4% in the first quarter. State of Wyoming now owns 42,520 shares of the company’s stock valued at $352,000 after acquiring an additional 3,638 shares during the period. Headlands Technologies LLC boosted its position in shares of CryoPort by 14.5% in the second quarter. Headlands Technologies LLC now owns 38,742 shares of the company’s stock valued at $608,000 after acquiring an additional 4,906 shares during the period. Quantinno Capital Management LP grew its stake in shares of CryoPort by 30.7% in the first quarter. Quantinno Capital Management LP now owns 43,966 shares of the company’s stock worth $364,000 after acquiring an additional 10,337 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new stake in shares of CryoPort in the third quarter worth $324,000. 92.90% of the stock is owned by institutional investors.

CryoPort Price Performance

The firm’s 50 day moving average price is $16.93 and its 200-day moving average price is $13.42. The firm has a market cap of $976.33 million, a price-to-earnings ratio of -21.47 and a beta of 1.89.

CryoPort (NASDAQ:CYRX – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. Analysts expect that CryoPort, Inc. will post -0.83 EPS for the current year.

About CryoPort

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.

See Also